Evaluating treatment effectiveness in small for gestational age children by optimizing growth hormone dose
Journal Title: Міжнародний ендокринологічний журнал - Year 2019, Vol 15, Issue 5
Abstract
Background. According to world statistics, about 5–10 % of newborns are small for gestational age (SGA). They can have inadequate rates of postnatal growth during first two years of life. This growth deficiency is observed throughout childhood and adolescence, which ultimately leads to short stature in adulthood. The purpose was to analyze the efficacy of different doses of recombinant growth hormone (rGH) therapy in order to correct growth in pre-pubertal children born small for gestational age. Materials and methods. Fifty children born small for gestational age (16 girls and 34 boys with mean age of 6.82 ± 0.36 years) with growth failure were examined. According to the results of clonidine and insulin tests, SGA patients were divided into two groups: group A — children without grown hormone deficiency (n = 34; 68 %), group B — patients with growth hormone deficiency (n = 16; 32 %). The control group included 34 persons (13 girls and 21 boys with mean age of 6.58 ± 0.38 years) with growth hormone deficiency. All patients received rGH treatment starting with a dose of 0.03 mg/kg/day according to the pituitary hormone deficiency protocol, and in case of slow growth rate, the dose was gradually increased to 0.05 mg/kg/day in group B patients. Results. A significant slowdown in growth acceleration in the first 6 months of rGH treatment at dose of 0.033 mg/kg/day was found in SGA patients without grown hormone deficiency (p < 0.05). The rGH treatment at a dose of 0.05 mg/kg/day for the next 6 months showed a statistically significant increase in growth standard deviation score (SDS) of SGA patients without growth hormone deficiency (–2.00 ± 0.14 SDS vs. –2.58 ± 0.15 SDS in the first 6 months with rGH dose of 0.033 mg/kg/day) (p < 0.05). Conclusions. The optimal dose of rGH treatment in small for gestational age children with growth hormone deficiency is 0.033 mg/kg/day, and in SGA patients without growth hormone deficiency — 0.05 mg/kg/day.
Authors and Affiliations
O. V. Bolshova, N. M. Muz
Keywords
Related Articles
- EP ID EP660839
- DOI 10.22141/2224-0721.15.5.2019.180041
- Views 63
- Downloads 0
Modern View on the Pathogenetic Therapy of Diabetic Polyneuropathy
The article deals with the treatment of diabetic polyneuropathy (DPN) using Actovegin. The results of research on the effectiveness of this drug in 200 patients with diabetes mellitus (aged from 19 to 88 years) are provi...
Diagnosis of Diabetic Encephalopathy According to Psychometric Tests in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
55 patients with type 2 diabetes mellitus, nonalcoholic fatty liver disease and encephalopathy were examined, there were 31 women (56.4 %) and 24 men (43.6 %). During the examination we assessed parameters of psychometri...
Role of Obesity in the Progression of Diabetic Nephropathy in Patients with Diabetes Mellitus (Literature Review)
The prevalence of obesity has risen proportionally to epidemic and continues to be a major health problem worldwide. The high prevalence of obesity is closely associated with the increased incidence of chronic diseases,...
Opportunities of Neurometabolic Therapy in the Treatment of Neurological Complications of Diabetes Mellitus
The review describes the effect of neurometabolic therapy with Actovegin on glucose uptake, as well as antioxidant, antihypoxant and other mechanisms of action of the drug. The possibilities of neurometabolic therapy in...
Complex Clinical-Laboratory and Cytological Study of Cervical and Vaginal Discharge in Women with Endocrinopathies
Cytological examination is one of basic methods for morphological analysis of biological material. It consists in the evaluation of characteristics of the morphological structure of cellular elements in cytological speci...